1 results match your criteria: "UKHaemophilia Centre and Haemostasis Unit[Affiliation]"
A study to assess the immunogenicity, reactogenicity and safety of hepatitis A vaccine administered subcutaneously to patients with congenital coagulation disorders.
Haemophilia
October 1996
Academic Unit of Travel Medicine and Vaccines, Royal Free Hospital School of Medicine, Rowland Hill Street, London NW3 2PF, UKHaemophilia Centre and Haemostasis Unit, Royal Free Hampstead NHS Trust, London NW3 2QG, UKSmithKline Beecham Pharmaceuticals, Mundells, Welwyn Garden City, Herts. AL7 1EY, UK.
Article Synopsis
- The study aimed to evaluate the effectiveness and safety of an inactivated hepatitis A vaccine in patients with congenital coagulation disorders.
- The vaccine was administered subcutaneously to 97 participants, which included both adult and child groups, showing a high seroconversion rate of 90% overall, with 100% in children and 85% in adults.
- It was found to be well-tolerated with fewer side effects after subsequent doses, and seroconversion rates were notably lower in subjects with low CD4 counts, particularly among HIV-positive adults.